A multi-center, double-blind, randomized, placebo-controlled, parallel-group, multiple-ascending-dose study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of R1511 in type 2 diabetic (T2D) patients.

Trial Profile

A multi-center, double-blind, randomized, placebo-controlled, parallel-group, multiple-ascending-dose study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of R1511 in type 2 diabetic (T2D) patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs R 1511 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2008 Status changed from recruiting to completed, according to clinicaltrials.gov.
    • 16 Jul 2008 The expected completion date for this trial is now 1 Jan 2009, according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top